802 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Uptrend
Article Searches
Stocks To Watch: Tech Earnings Bellwethers Set To Test Rally https://seekingalpha.com/article/4212924-stocks-watch-tech-earnings-bellwethers-set-test-rally?source=feed Oct 20, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Novartis Reports Positive Long-Term Data From Cosentyx Trials http://www.zacks.com/stock/news/328979/novartis-reports-positive-long-term-data-from-cosentyx-trials?cid=CS-ZC-FT-328979 Oct 18, 2018 - Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications.
This Big Pharma Staple Is A Great Defensive Pick For Volatile Times https://seekingalpha.com/article/4212309-big-pharma-staple-great-defensive-pick-volatile-times?source=feed_sector_healthcare Oct 18, 2018 - The rapid up and down swings in the capital markets lately is enough to make the most seasoned investors dizzy.Healthcare stocks can become especially dangerous during these times.GlaxoSmithKline coul
Healthcare 16-24% Target Net Gains Pace WallStars For October https://seekingalpha.com/article/4211623-healthcare-16minus-24-percent-target-net-gains-pace-wallstars-october?source=feed_all_articles Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
Retirement: How To Manage Risks And Prepare For The Next Downturn https://seekingalpha.com/article/4211145-retirement-manage-risks-prepare-next-downturn?source=feed Oct 13, 2018 - The continuing bull market of the last 10 years has helped almost everyone. Moreover, the index investing has been the king.The bull market may continue for the foreseeable future, but eventually, the
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal http://www.zacks.com/stock/news/327759/pharma-stock-roundup-abbv-nvs-humira-biosimilar-agreement-bmys-new-cancer-deal?cid=CS-ZC-FT-327759 Oct 12, 2018 - AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
Novartis Presents Positive Data on Sickle Cell Disease Drug http://www.zacks.com/stock/news/327300/novartis-presents-positive-data-on-sickle-cell-disease-drug?cid=CS-ZC-FT-327300 Oct 10, 2018 - Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.
Altimmune Declines Too Much https://seekingalpha.com/article/4210760-altimmune-declines-much?source=feed_sector_healthcare Oct 09, 2018 - Altimmune, Inc. is a clinical stage immunotherapeutics company developing robust and durable immune responses intended for the prevention and treatment of several illnesses.The market is too pessimist
Merck Reports Positive Efficacy Data from Phase III HIV Study http://www.zacks.com/stock/news/326549/merck-reports-positive-efficacy-data-from-phase-iii-hiv-study?cid=CS-ZC-FT-326549 Oct 05, 2018 - Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.
Gilead Announces Positive Data From Ongoing Biktarvy Study http://www.zacks.com/stock/news/326456/gilead-announces-positive-data-from-ongoing-biktarvy-study?cid=CS-ZC-FT-326456 Oct 05, 2018 - Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.

Pages: 123456...81

Page 1>

Related Companies

Name Exchange Price Mkt Cap
AZN Astrazeneca PLC NYSE $37.56 $95.16B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for GlaxoSmithKline PLC